Form 4: Vertex EVP Sells 14,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Vertex Pharmaceuticals' EVP, Charles F. Wagner Jr., sold 14,000 shares of common stock for approximately $6.38 million through a pre-arranged 10b5-1 trading plan.
Summary
- Charles F. Wagner Jr., Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions.
- Sold a total of 14,000 shares of Common Stock on December 3, 2025.
- The sales were executed in two separate transactions: 7,000 shares at $451 per share and another 7,000 shares at $461 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan, which was established on May 9, 2025.
- Following these sales, Mr. Wagner directly beneficially owns 37,725 shares of Common Stock.
Sentiment
Score: 5
Explanation: A Form 4 filing, especially one under a 10b5-1 plan, is a routine disclosure of an insider transaction. It is neutral in sentiment as it reflects a pre-planned event rather than a reaction to new company performance or strategic shifts. While insider selling can sometimes be viewed negatively, the pre-arranged nature mitigates immediate concerns.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of insider stock transactions and does not provide specific insights into broader industry trends or competitive landscape for the biotechnology and pharmaceutical sector. Such transactions are common for executives managing personal portfolios or exercising stock options.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it is not based on new, non-public information. The impact is generally minimal for routine 10b5-1 sales.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date Mr. Wagner's company approved trading plan under Rule 10b5-1 was entered into. |
| 12/03/2025 | Date of the reported stock transactions (sale of common stock). |
| 12/05/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Charles F. Wagner Jr.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.